Microglial activation might protect against accumulation of Aβ and tau aggregates over time in non‐demented Aβ‐positive individuals

The past years have seen a turning point in the view of the impact of microglia in Alzheimer’s disease (AD). In particular, the activation of soluble TAM receptors and the TREM‐2 dependent transition from a homeostatic to a disease‐associated microglia stage 2 state (DAM2) seem to play relevant roles in AD. However, a comprehensive analysis of microglial‐associated biomarkers and their associations with longitudinal accumulation of amyloid‐β (Aβ) and tau aggregates in humans has not been performed yet.